Mitchell Gendel Acquires 2,500 Shares of Tilray Brands (NASDAQ:TLRY) Stock

Tilray Brands, Inc. (NASDAQ:TLRY) General Counsel Mitchell Gendel purchased 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was bought at an average cost of $4.43 per share, with a total value of $11,075.00. Following the acquisition, the general counsel owned 124,883 shares of the company’s stock, valued at approximately $553,231.69. The trade was a 2.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Tilray Brands Trading Up 2.6%

Shares of Tilray Brands stock traded up $0.12 during trading hours on Friday, hitting $4.55. The company’s stock had a trading volume of 1,216,789 shares, compared to its average volume of 4,317,777. The stock has a market cap of $530.89 million, a price-to-earnings ratio of -4.23 and a beta of 1.90. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.37 and a current ratio of 2.21. Tilray Brands, Inc. has a twelve month low of $3.67 and a twelve month high of $23.20. The firm has a fifty day moving average of $4.60 and a 200-day moving average of $6.09.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings data on Tuesday, July 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.76%. The company had revenue of $281.71 million during the quarter, compared to analysts’ expectations of $246.30 million. Research analysts forecast that Tilray Brands, Inc. will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TLRY shares. Wall Street Zen cut shares of Tilray Brands from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings lowered Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. TD Securities raised Tilray Brands to a “strong-buy” rating in a research note on Friday, July 31st. Finally, TD Cowen dropped their price objective on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tilray Brands currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC acquired a new position in shares of Tilray Brands in the fourth quarter worth $38,000. Essential Partners LLC increased its position in shares of Tilray Brands by 110,137.5% during the first quarter. Essential Partners LLC now owns 8,819 shares of the company’s stock worth $57,000 after acquiring an additional 8,811 shares during the period. Engineers Gate Manager LP acquired a new stake in Tilray Brands in the 4th quarter valued at about $126,000. R Squared Ltd purchased a new position in Tilray Brands in the first quarter worth approximately $94,000. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Tilray Brands during the 1st quarter worth $96,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.